Molecular Profiling in Glioblastoma: Prelude to Personalized Treatment

被引:16
|
作者
Mladkova, Nikol [1 ]
Chakravarti, Arnab [1 ]
机构
[1] Massachusetts Gen Hosp, Dept Radiat Oncol, Ctr Canc, Boston, MA 02114 USA
关键词
PHASE-II TRIAL; MALIGNANT GLIOMAS; IMATINIB MESYLATE; RECEPTOR; CLASSIFICATION; TEMOZOLOMIDE; RAPAMYCIN; SURVIVAL; THERAPY; UPDATE;
D O I
10.1007/s11912-009-0009-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The purpose of this review is to provide an up-to-date summary of the current knowledge and understanding of the molecular alterations and pathways relevant to the clinical outcome of glioblastoma patients and their potential use in designing personalized treatment for these patients. This article also discusses the potential of molecular profiling as a diagnostic modality, possible therapeutic implications of MGMT promoter methylation, the targeted inhibition of angiogenesis, and assessment of the tumor's molecular background with respect to PI3K/AKT pathway activation and associated molecules (EGFR, EGFRvIII, PTEN).
引用
收藏
页码:53 / 61
页数:9
相关论文
共 50 条
  • [31] Molecular Profiling in the Diagnosis of a Case of a Metastatic Glioblastoma to the Liver
    Schwartz, S.
    Varma, H.
    JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2024, 83 (06): : 515 - 515
  • [32] Bioinformatics data profiling tools: A prelude to metabolic profiling
    Ganesan, Natarajan
    Kalyanasundaram, Bala
    Velauthapllai, Mahe
    PACIFIC SYMPOSIUM ON BIOCOMPUTING 2007, 2007, : 127 - +
  • [33] Apolipoprotein profiling as a personalized approach to the diagnosis and treatment of dyslipidaemia
    Ruhaak, L. Renee
    van der Laarse, Arnoud
    Cobbaert, Christa M.
    ANNALS OF CLINICAL BIOCHEMISTRY, 2019, 56 (03) : 338 - 356
  • [34] Immunological profiling as a means to invigorate personalized cancer treatment
    Hegmans, Joost P. J. J.
    Aerts, Joachim G. J. V.
    ONCOIMMUNOLOGY, 2013, 2 (08)
  • [35] APOLIPOPROTEIN PROFILING AS A PERSONALIZED APPROACH TO THE DIAGNOSIS AND TREATMENT OF DYSLIPIDEMIA
    Cobbaert, C.
    Ruhaak, R.
    van der Laarse, A.
    ATHEROSCLEROSIS, 2019, 287 : E165 - E165
  • [36] Should biomarkers be used to design personalized medicine for the treatment of glioblastoma?
    Weller, Michael
    Wick, Wolfgang
    Hegi, Monika E.
    Stupp, Roger
    Tabatabai, Ghazaleh
    FUTURE ONCOLOGY, 2010, 6 (09) : 1407 - 1414
  • [37] Improving personalized glioblastoma treatment by forecasting therapy like a storm
    Galukande, Natasha
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2013, 13 (04) : 349 - 349
  • [38] Personalized treatment strategies in glioblastoma: MGMT promoter methylation status
    Thon, Niklas
    Kreth, Simone
    Kreth, Friedrich-Wilhelm
    ONCOTARGETS AND THERAPY, 2013, 6 : 1363 - 1372
  • [39] Molecular Profiling of Gastric Cancer: Toward Personalized Cancer Medicine
    Nadauld, Lincoln D.
    Ford, James M.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (07) : 838 - 839
  • [40] Molecular Neuropathology in Practice: Clinical Profiling and Integrative Analysis of Molecular Alterations in Glioblastoma
    Nasrallah, MacLean P.
    Binder, Zev A.
    Oldridge, Derek A.
    Zhao, Jianhua
    Lieberman, David B.
    Roth, Jacquelyn J.
    Watt, Christopher D.
    Sukhadia, Shrey
    Klinman, Eva
    Daber, Robert D.
    Desai, Arati
    Brem, Steven
    O'Rourke, Donald M.
    Morrissette, Jennifer J. D.
    ACADEMIC PATHOLOGY, 2019, 6